Osteoporosis in a Premenopausal Woman: Whether to Treat, and With What
A single patient whose low bone density doesn't fit the population most osteoporosis drugs were studied in. The disagreement isn't only which drug — several are genuinely off the table for her — it's whether treating at all, this early, is the right call.
Renata F., a 34-year-old woman, has spent the past several years building a landscaping business with her older brother, work that keeps her lifting mulch bags and pushing wheelbarrows most days she isn't meeting clients. A dull, persistent mid-back ache she had chalked up to the physical demands of the job turned out, on imaging ordered after weeks without improvement, to be a compression fracture at L2 — not from a fall or an accident, just there, on a film she expected to show a muscle strain.
Her workup found no secondary cause to explain it: thyroid function normal, calcium and PTH normal, celiac panel negative, no eating disorder history, no glucocorticoid exposure, regular menses with no history of amenorrhea. What it did find was a lumbar spine Z-score of −2.8. A Z-score rather than a T-score, because at 34 the comparison that means anything is against women her own age — and by that comparison she sits nearly three standard deviations below them, with a fracture already sustained to prove the number is describing something real. Her mother was diagnosed with osteoporosis at 58, which is early enough to be interesting and too nonspecific to act on. She and her husband have been discussing trying to conceive within the next two to three years, a plan she raised herself before anyone asked. That timeline is what shapes the disagreement, because the agents the group would reach for reflexively in an older patient carry specific, non-interchangeable concerns for a woman planning pregnancy. Bisphosphonates are retained in the skeleton and released for years after the last dose, with animal-model evidence of fetal harm persisting past discontinuation — a liability that belongs to that class specifically, not to treatment in general. Teriparatide does not carry it. What it carries instead is a much thinner evidence base in her population: Cohen and colleagues studied it in premenopausal women with idiopathic osteoporosis and found meaningful density gains, but in a pilot-scale study, which is population-matched evidence rather than an extrapolation from postmenopausal trials and also nowhere near the weight of one.
Which agents her own timeline actually rules out
I'd hold off on pharmacologic treatment. Premenopausal osteoporosis without a secondary cause is genuinely understudied — most of the trial evidence behind our standard agents comes from postmenopausal women — and she's hoping to conceive in the next few years, which effectively rules out bisphosphonates given their long skeletal retention and the animal-model concern for fetal harm even after the drug is stopped.
The fracture itself is what I don't think we can defer on. A vertebral compression fracture with no significant trauma is a real signal at any age — and leaving her bone loss untreated through her reproductive-planning years risks her entering a pregnancy from a worse starting point, not a neutral one.
I hear the evidence-gap concern, and it's legitimate — I'm not dismissing it, I'm arguing that a documented fragility fracture is exactly the kind of individual signal that should outweigh population-level uncertainty, not get deferred by it.
I think the treat-or-wait framing is actually hiding the real decision. The specific liability ruling out bisphosphonates for her — long skeletal retention, persisting after the drug is stopped — doesn't apply the same way to teriparatide. Cohen and colleagues' pilot study of teriparatide specifically in premenopausal women with idiopathic osteoporosis found meaningful bone density gains without the retention concern bisphosphonates carry — small, but real, population-matched evidence, not an extrapolation from postmenopausal trials.
That reframes this from "treat this young or not" to "which agent actually fits her stated two-to-three-year timeline" — and on that narrower question, teriparatide is the one that doesn't require choosing between treating her fracture and honoring her reproductive plans.
Agreed: start teriparatide rather than a bisphosphonate, and plan for a defined treatment course with reassessment before she and her husband move forward with conception, given the drug's shorter required duration and lack of persistent skeletal retention.
Not fully settled: exactly how much time should elapse between stopping teriparatide and attempting conception — the endocrinologist and pharmacologist gave different informal estimates, and both agreed the honest answer is that premenopausal-specific data to pin that interval down precisely doesn't really exist yet.